Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

Real-time Quote. Real-time Tradegate - 07/01 01:42:02 pm
91.305 EUR   +0.28%
10:40a MERCK KGAA : Results of Pivotal TAILOR Study Confirm Addition of Erb..
08:10a MERCK KGAA : Successful Cooperation Between Merck and Agrimer in Mar..
06/28 MERCK KGAA : Expands Industry-Leading Emprove® Program to Include Fi..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck KGaA May Withdraw Research from Portugal over Debt-Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 08:28am CEST

German chemical company Merck KGaA (>> Merck KGaA) may withdraw future investments for research projects in Portugal worth tens of millions of euros unless the government hospitals stick to the agreed-upon debt repayments, German daily newspaper Financial Times Deutschland reports Monday.

Merck Portugal's manager Fritz Sacher told the paper the company's research projects are long-term and require mutual trust as a basis. "The Portuguese government's lacking payment habits undermine this trust," he is quoted as saying.

Portuguese government hospitals owe the pharmaceutical industry a total of more than 1.5 billion euros ($1.84 billion) and companies have to wait nearly 550 days on average until invoices are paid, FTD reports.

Some companies, including Roche Holding AG (ROG.VX), have already halted the sale of medications on credit to highly indebted countries like Portugal, Greece, Spain and Italy until outstanding debts are paid, the paper notes, but for many companies such drastic steps are difficult as they carry responsibility for people's wellbeing.

Withdrawing research projects is a way of putting pressure on the government, as Portugal is an attractive location for research investments, FTD says. "The conditions for certain research and human studies are as good as in the U.S., but it's significantly more cost-effective in Portugal," Sacher told the paper.

Newspaper website: http://www.ftd.de

Write to the Frankfurt Bureau at djnews.frankfurt@dowjones.com

Stocks mentioned in the article : Merck KGaA
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on MERCK KGAA
10:40a MERCK KGAA : Results of Pivotal TAILOR Study Confirm Addition of Erbitux to FOLF..
08:10a MERCK KGAA : Successful Cooperation Between Merck and Agrimer in Marine-Derived ..
06/28 MERCK KGAA : Expands Industry-Leading Emprove® Program to Include Filtration and..
06/28 EMD MILLIPORE : Verifi(Ab)le – Neuroscience Antibodies
06/28 MERCK KGAA : to Develop Next-Generation Purification Processes with Internationa..
06/25 MERCK : OBS Pakistan acquiring Merck Serono
06/24DJMERCK KGAA : Says It Has No Immediate Plans to Cut Jobs in UK
06/16 ASCO 2016 : Pivotal Avelumab Study Shows Positive Results in Metastatic Merkel C..
06/16 MERCK KGAA : Men Having Babies' Gay Parenting Assistance Program Expanded to Hel..
06/16 MERCK KGAA : Epichem Successful in AusTrade Grant
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials